1FE-LSD

1FE-LSD is a novel lysergamide research chemical that entered the European market in 2024, representing the newest generation of acylated LSD prodrugs following 1BP-LSD (2023). Its full chemical name is 1-(2-fluoroethanoyl)-lysergic acid diethylamide — an LSD-25 derivative bearing a fluoroethanoyl group at the nitrogen of position 1 on the indole ring. Like its predecessors in the 1-acyl-LSD series, 1FE-LSD functions as an inactive precursor that is converted in vivo to the parent compound LSD-25 through enzymatic hydrolysis. As of April 2026, 1FE-LSD is not scheduled under the German Narcotics Act (BtMG) or the New Psychoactive Substances Act (NpSG) and is sold as a research chemical not intended for human consumption.

Among the currently available legal LSD prodrugs, 1FE-LSD has rapidly gained popularity. It is frequently regarded as the most refined member of the series due to its comparatively faster onset, lower body load, and higher potency per microgram relative to 1BP-LSD.

Chemistry

1FE-LSD belongs to the family of 1-acylated lysergamides: LSD-25 derivatives in which an acyl group is covalently bound to the nitrogen atom at position 1 of the indole ring system. The defining structural feature of 1FE-LSD is the fluoroethanoyl group (F–CH₂–CO–), a fluorine-substituted acetyl moiety. This fluorine substitution imparts notable chemical stability to the molecule — fluorine's strong electronegativity and compact atomic radius make the C–F bond one of the strongest in organic chemistry, contributing to resistance against oxidative and hydrolytic degradation.

The approximate molecular mass is ~395 g/mol, placing it below 1BP-LSD (~407 g/mol) but above LSD-25 (~323 g/mol). This lower mass relative to 1BP-LSD means that each microgram of 1FE-LSD contains a higher molar proportion of active precursor, explaining its greater potency per unit weight.

The compound is commercially available as blotters (typically 200 µg) and micro pellets (10 µg for microdosing). Like all lysergamide prodrugs, 1FE-LSD is sensitive to degradation by heat, UV radiation, moisture, and oxidation. Storage in opaque, airtight packaging at room temperature or below is recommended. The fluorine atom may confer slightly improved shelf stability compared to non-fluorinated analogues, though controlled stability studies have not been published.

It is essential to distinguish 1FE-LSD from the structurally unrelated 1F-LSD (1-(furan-2-carbonyl)-LSD, also known as SYN-L-005, C₂₅H₂₇N₃O₃, 417.5 g/mol). Despite the similar abbreviation, 1F-LSD carries a furanyl ring at position 1, an entirely different pharmacophore. The two compounds should not be confused.

Pharmacology

1FE-LSD functions as a prodrug of LSD-25. Following oral ingestion, the fluoroethanoyl group at position 1 is cleaved by esterases and hepatic enzymes, liberating free LSD-25 into systemic circulation. The fluoroethanoyl group appears to undergo hydrolysis more rapidly than the larger acyl moieties of 1BP-LSD and 1V-LSD. This faster metabolic activation is the most likely explanation for the characteristically shorter onset time of 30–75 minutes reported by users, compared to 45–90 minutes for 1BP-LSD.

Once converted, the pharmacological profile is identical to LSD-25. The active metabolite is a potent partial agonist at serotonin 5-HT₂A receptors — the primary molecular target responsible for the psychedelic state — as well as 5-HT₂B, 5-HT₂C, 5-HT₁A, and various dopamine receptors (D₁, D₂). Intracellular signalling proceeds via β-arrestin-2 recruitment, believed to mediate the prolonged duration and distinctive phenomenology of lysergamide experiences. Additionally, LSD occupies the 5-HT₂A receptor binding pocket in a manner that causes a "lid" formed by extracellular loop 2 (ECL2) to close over the molecule, contributing to its unusually long receptor residence time and extended duration of action.

Owing to its lower molecular mass, 1FE-LSD delivers more molecules of active LSD per microgram of substance compared to 1BP-LSD. In practical terms, it is approximately 15–20% more potent per unit weight than 1BP-LSD. 125 µg of 1FE-LSD is commonly reported to produce effects equivalent to approximately 150 µg of 1BP-LSD or 100–120 µg of LSD-25, though individual metabolic variation can shift this ratio considerably.

Complete cross-tolerance develops with all serotonergic psychedelics acting at 5-HT₂A receptors, including psilocybin, mescaline, DMT, and all other LSD prodrugs. Tolerance dissipates over approximately 10–14 days.

Effects

The subjective effects of 1FE-LSD mirror those of LSD-25, with some nuanced differences in character that users frequently attribute to the prodrug conversion profile:

• Visual effects: enhanced colour saturation, geometric patterning, fractal structures, trailing and tracers, surface "breathing," and at higher doses vivid closed-eye imagery. Visual intensity at equipotent doses is indistinguishable from LSD-25 or 1BP-LSD.
• Cognitive effects: pronounced introspection, conceptual thinking, thought acceleration, altered time perception, and synesthetic crossover between senses. Many users describe the 1FE-LSD headspace as exceptionally clear and lucid compared to other lysergamide prodrugs — a quality frequently emphasised in comparison reports.
• Emotional effects: euphoria, connectedness, emotional sensitivity and lability, occasional anxiety or confusion at high doses or in unfavourable settings.
• Physical effects: pupil dilation (mydriasis), modest heart rate increase, mild nausea during the comeup, jaw tension. The body load is notably lower than with 1BP-LSD or 1V-LSD — a frequently cited reason for 1FE-LSD's growing popularity. Users describe the physical experience as light, clean, and energetic rather than heavy or sedating.

The onset is faster than most prodrugs at 30–75 minutes, reaching full peak effects within 1.5–2.5 hours after ingestion. The overall character is frequently described as clear, focused, and energetic, making it the preferred choice among users who prioritise mental clarity and minimal physical side effects. The total duration at a common dose is 8–12 hours, with residual aftereffects lasting up to 24 hours.

Microdosing (8–15 µg, sub-perceptual) is a popular use case. At these doses no overt psychedelic effects occur; users report enhanced focus, clarity, and a subtle uplift in mood and energy. Microdose effects typically last 6–8 hours. The faster onset compared to 1BP-LSD (30–45 min vs 45–60 min for microdoses) makes timing more predictable for productivity use.

Harm Reduction

• Novelty and limited data: 1FE-LSD appeared on the market in 2024. No peer-reviewed pharmacological or toxicological studies specific to this compound have been published. All dosage and safety information is derived from user reports and extrapolation from the well-characterised pharmacology of LSD-25 and related prodrugs. Exercise additional caution accordingly.
• Potency awareness: 1FE-LSD is more potent per microgram than 1BP-LSD. Users switching between prodrugs must adjust doses downward. A direct 1:1 microgram swap can result in a significantly stronger experience than anticipated.
• Serotonin syndrome risk: combining 1FE-LSD with serotonergic drugs (SSRIs, SNRIs, MAOIs, tramadol, lithium) can cause additive or synergistic serotonergic toxicity. The interaction with lithium is particularly dangerous and may trigger seizures.
• Cardiovascular considerations: LSD-25 modestly raises heart rate and blood pressure. Individuals with pre-existing cardiac conditions or uncontrolled hypertension should exercise caution.
• Psychological vulnerability: psychedelics can precipitate or exacerbate psychotic episodes in individuals with a personal or family history of schizophrenia spectrum disorders or bipolar disorder. Screening for these conditions is strongly advisable before use.
• HPPD (Hallucinogen-Persisting Perception Disorder): a small fraction of psychedelic users develop persistent visual disturbances after use. Risk factors include high doses, frequent use, pre-existing anxiety, and cannabis co-use.
• Reagent testing: Ehrlich's reagent produces a purple/violet reaction with indole-containing lysergamides, confirming the presence of an LSD-type compound. Hofmann reagent provides secondary confirmation. These tests cannot distinguish between individual LSD prodrugs but can rule out dangerous substitutes like NBOMes.
• Do not combine prodrugs: mixing 1FE-LSD with 1BP-LSD or another LSD prodrug in the same session is discouraged. Both are converted to the same active compound (LSD-25), making dosage unpredictable due to different conversion kinetics. Choose one substance and dose deliberately.

Related Compounds

• LSD-25 (lysergic acid diethylamide) — the parent compound to which 1FE-LSD is converted in vivo
• 1BP-LSD (1-butanoylpiperidyl-LSD, ~407 g/mol) — a closely related but slightly less potent prodrug with a slower onset and more pronounced body load; available since 2023
• 1F-LSD (1-(furan-2-carbonyl)-LSD, 417.5 g/mol, SYN-L-005) — a structurally unrelated compound despite the similar abbreviation; carries a furanyl ring rather than a fluoroethanoyl group
• 1P-LSD (1-propionyl-LSD) — the first widely available LSD prodrug; scheduled in Germany since 2019
• 1cP-LSD (1-cyclopropionyl-LSD) — scheduled in Germany since 2022
• 1V-LSD (1-valeroyl-LSD) — scheduled under the German NpSG since July 2022
• 1D-LSD — a currently legal lysergamide prodrug
• 1S-LSD — another legal lysergamide derivative
• 1B-LSD (1-butanoyl-LSD, ~393 g/mol) — an earlier prodrug now scheduled under the German NpSG; not to be confused with 1BP-LSD